Patente Mundial del Yondelis . Objetivo crear un Hermano del ET-743 ??? . Seria el ET-770 .

INTERMEDIATE AND PROCESS OF PREPARATION OF ECTEINASCIDIN SUCH AS ECTEINASCIDINES-583, 597 USING SUCH INTERMEDIATE .

Publication number: WO2007045686
Publication date: 2007-04-26
Inventor: ZHU JIEPING (FR); BOIS-CHOUSSY MICHELE (FR); CHEN JINCHUN (FR); CHEN XIAOCHUAN (FR)
Applicant: CENTRE NAT RECH SCIENT (FR); ZHU JIEPING (FR); BOIS-CHOUSSY MICHELE (FR); CHEN JINCHUN (FR); CHEN XIAOCHUAN (FR)
Classification:
- international:
- European:
Application number: WO2006EP67611 20061020
Priority number(s): US20050728295P 20051020; EP20050292203 20051020



Abstract of WO2007045686
The present invention concerns an intermediate of the following formula (I) in which R1 and R2 represent independently of each other a C1-C12 alkyl group, a (C1-C12 alkoxy)carbonyl group, optionally substituted by one, two or three halogen atom, a (C2-C12 alkenyloxy) carbonyl group, an acyl group, a aryl(C1-C12)alkyl group, an arylalkoxy carbonyl group, a (C1-C12 alkyl)sulfonyl group or an arylsulfonyl group, R3 represents a O-protecting group, R4 and R5 represent independent ly of each other a hydrogen atom or a O-protecting group, R6 represent a O-protecting group and R7 represent a C1-C12 alkyl group or -OR6 and -OR7 form together a group -OCH2O-. The present invention concerns also a process of preparation of the intermediate and its use for the preparation of Ecteinascidin 743 and Ecteinascidin-770.

Patente Mundial del Yondelis . Objetivo : Disminuir su Toxicidad y con ello se Aumentaria su Potencial AntiCancerigeno .

USE OF PARP-1 INHIBITORS

Publication number: WO2007062413
Publication date: 2007-05-31
Inventor: SCOTTO KATHLEEN A (US); MANDOLA MICHAEL (US)
Applicant: UNIV NEW JERSEY MED (US); SCOTTO KATHLEEN A (US); MANDOLA MICHAEL (US)
Classification:
- international: A61K31/7076; A61K31/498; A61K31/7042; A61K31/498;
- European:
Application number: WO2006US61254 20061127
Priority number(s): US20050739536P 20051125

Abstract of WO2007062413
A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-I inhibitor effective to increase the cytotoxic effect of ET-743 on the tumor cell population. Anti-tumor compositions containing a therapeutically effective amount of ET-743 and an amount of a PARP-I inhibitor effective to increase the tumor cytotoxicity of the ET-743 are also presented.

Cientificos de las universidades de Suiza e Italia descubren el por qué se reproducen las células cancerígenas.

La evidencia de que el exceso de grasa corporal aumenta el riesgo de cáncer es más fuerte ahora que nunca antes .

WASHINGTON, 31 de octubre /PRNewswire-USNewswire/

según un informe que marca un hito histórico difundido hoy
por el World Cancer Research Fund (Fondo Mundial para la Investigación del
Cáncer -- WCRF, según sus siglas en inglés) y el American Institute for Cancer
Research (Instituto Americano para la Investigación del Cáncer -- AICR, según
sus siglas en inglés). La evidencia que vincula el consumo de alcohol, de
carnes rojas y de carne procesada a un aumento del riesgo también resulta
convincente.